Impact of Rapid Detection of MRSA

Withdrawn

• Conditions: Staphylococcus Aureus Infections

• Registration Number: NCT02027389
• Lead Sponsor: Mayo Clinic

Brief Summary

The objective of this study is to evaluate the impact of the Alere\™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-12-27
• Study Start: 2014-01
• Study First Submitted QC: 2014-01-02
• Study First Posted: 2014-01-06
• Primary Completion: 2016-07
• Study Completion: 2016-07
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-11
• Last Update Posted: 2018-02-13

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods	within first 7 days of culture result

Secondary Outcome Measures

Name	Time	Method
Time (in hours) to identification of MRSA.	within first 3 days of culture result
Vancomycin days of therapy following S. aureus culture result	during the 2 weeks following culture result

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States